SLS

Business Context and Reporting Period

Company: SELLAS Life Sciences Group, Inc. (SLS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: SELLAS is a late-stage clinical biopharmaceutical company focused on novel cancer therapeutics. Its lead candidates are galinpepimut-S (GPS), a WT1-targeting immunotherapy, and SLS009 (tambiciclib), a CDK9 inhibitor. The company operates as a single segment and has not yet generated product sales revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose by $3.2 million (53%) year-over-year. R&D expenses increased by $1.9 million, primarily driven by a $1.3 million increase in manufacturing costs for GPS in preparation for a potential Biologics License Application (BLA) and $0.4 million in increased clinical/regulatory consulting. G&A expenses increased by $1.3 million, largely due to $0.6 million in legal fees related to the 3D Medicines arbitration.
• Significant Liquidity Improvement: Cash and cash equivalents increased from $71.8 million at the end of 2025 to $107.1 million at the end of Q1 2026. This was driven by $44.1 million in proceeds from the exercise of 28.2 million warrants during the quarter.
• Share Count Expansion: Outstanding common shares increased from 153.1 million (Dec 31, 2025) to 181.3 million (Mar 31, 2026) due to warrant exercises and employee stock purchase plan activity.

Outlook, Risks, and Management Commentary

• Clinical Progress:
  • GPS (REGAL Study): The Phase 3 study in AML has completed enrollment. The interim analysis (60 events) was completed in Jan 2025 with a recommendation to continue. As of May 11, 2026, 78 events have been recorded; the final analysis requires 80 events.
  • SLS009: The Phase 2 trial in relapsed/refractory AML met primary endpoints. The FDA recommended advancing to a first-line therapy study, which began enrollment in Q1 2026. A European study via the IMPACT-AML network was also initiated.
• Liquidity and Capital Resources: Management expects current cash ($107.1 million) plus $7.5 million in post-period warrant proceeds to fund operations for at least the next 12 months. The company entered a $150 million At-The-Market (ATM) equity offering program in March 2026 but has not yet sold shares under it.
• Legal Contingency: A binding arbitration against 3D Medicines (regarding milestone payments and development efforts in Greater China) is ongoing. A hearing was held in Jan 2026; the final determination is pending. Potential future milestones under this agreement total $191.5 million but are variable and not under the company's control.
• Risks: The company has an accumulated deficit of $283.4 million and expects to continue incurring losses. Future funding may be required, which could be dilutive. Success depends on clinical trial outcomes and regulatory approvals.

Investor Verification Checklist

• Warrant Exercise Impact: Verify the dilution effect of the 28.2 million shares issued in Q1 and the subsequent 4.7 million shares issued post-period.
• Arbitration Outcome: Monitor the status of the arbitration against 3D Medicines, as a favorable outcome could unlock significant milestone revenue ($13 million+ in disputed payments).
• REGAL Study Timeline: Track the timing of the 80th event in the GPS Phase 3 trial, which triggers the final analysis and potential BLA filing.
• Burn Rate vs. Cash Runway: Confirm if the $107 million cash balance is sufficient given the increased R&D spend ($5.1M/quarter) and potential need for additional capital before commercialization.
• ATM Program Utilization: Watch for any sales under the new $150 million ATM facility, which could impact share price and dilution.